Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,321 | 209 | 1,087 |
| Samples | 636 | 141 | 482 |
| Peptides | 528 | 100 | 434 |
Function
GAK · Cyclin G associated kinase
In all eukaryotes, the cell cycle is governed by cyclin-dependent protein kinases (CDKs), whose activities are regulated by cyclins and CDK inhibitors in a diverse array of mechanisms that involve the control of phosphorylation and dephosphorylation of Ser, Thr or Tyr residues. Cyclins are molecules that possess a consensus domain called the 'cyclin box.' In mammalian cells, 9 cyclin species have been identified, and they are referred to as cyclins A through I. Cyclin G is a direct transcriptional target of the p53 tumor suppressor gene product and thus functions downstream of p53. GAK is an association partner of cyclin G and CDK5. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2015].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 513 amino-acid changes on canonical ENST00000314167 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GAK · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GAK – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 4/26 15% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Oral Cavity Carcinoma | 4/54 7% | 0/0 0% |
| Glioblastoma | 6/98 6% | 0/0 0% |
| Chordoma | 0/7 0% | 1/13 8% |
| Endometrial Carcinoma | 5/42 12% | 22/612 4% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 25/304 8% | 35/1390 3% |
| Burkitts Lymphoma | 1/32 3% | 7/196 4% |
| Melanoma | 7/210 3% | 63/1899 3% |
| Hodgkins Lymphoma | 3/16 19% | 1/122 1% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Gastric Carcinoma | 5/74 7% | 42/1809 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Colorectal Carcinoma | 10/143 7% | 59/3239 2% |
| Bladder Carcinoma | 2/58 3% | 18/956 2% |
| Other Solid Cancers | 1/94 1% | 27/1515 2% |
| Thyroid Gland Carcinoma | 2/45 4% | 22/1592 1% |
| Ovarian Carcinoma | 10/109 9% | 6/998 1% |
| Ewings Sarcoma | 4/63 6% | 0/262 0% |
| Neuroendocrine Tumour | 6/154 4% | 3/577 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 7/752 1% |
| Cervical Carcinoma | 1/35 3% | 4/422 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 9/810 1% |
| Biliary Tract Carcinoma | 1/54 2% | 9/950 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 22/2550 1% |
| Glioma | 1/52 2% | 19/2127 1% |
| Other Sarcomas | 3/69 4% | 4/699 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Kidney Carcinoma | 2/85 2% | 15/1862 1% |
Mutation Distribution
Where GAK is mutated · all tissues, split by cell line vs tissue
How many mutations in GAK were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,321 mutations in GAK
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|